Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- TOPICS／Asahi Kasei Publishes FY2007 IP Report
August 6, 2007
- SURVEY／Majority of Users Do not Obtain Viagra from Hospitals
August 6, 2007
- Kyowa Hakko Licenses New Antibody Engineering Technology to BioWa
August 6, 2007
- Merck to Acquire NovaCardia
August 6, 2007
- R&D NEWS IN BRIEF
August 6, 2007
- Eisai Licenses Eszopiclone from Sepracor
August 6, 2007
- Elmed Eisai Conducts PMS on 2 of Its Generic Products
August 6, 2007
- Kissei Enters into Agreement with Nuon Therapeutics on Rizaben
August 6, 2007
- GENERICS NEWS IN BRIEF
August 6, 2007
- Revised Therapeutic GL on Breast Cancer Published
July 30, 2007
- NEW PRODUCTS
July 30, 2007
- Eisai to Launch 3 Major Drugs by FY2011: Mr Naito
July 30, 2007
- Prices Should Not Be Cut during Patent Life If Yakkasa Is Smaller than “Dispensing Margins”: EFPIA
July 30, 2007
- Long-Listed Drugs Should Be Priced Higher Than Generics: Mr Ohyagi
July 30, 2007
- REGULATORY NEWS IN BRIEF
July 30, 2007
- Kyowa Hakko Committed to Successively Developing New Drugs: President Dr Matsuda
July 30, 2007
- 3rd Seminar on MR Mammography Fields Hottest Topics on Breast Cancer MRI
July 30, 2007
- Pfizer Expanding Supply of Information on JZOLOFT to PCP
July 30, 2007
- Pacemakers Are Much Higher-Priced in Japan Than in South Korea, Thailand: Survey
July 30, 2007
- Janssen to Differentiate Risperdal from Generics
July 30, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…